

PediRISE Feasibility

NCT06283251

Status	RECRUITING
Phase	Not Applicable
Sponsor	Dana-Farber Cancer Institute
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (16)

- Cohort 1: Poverty-exposed children with cancer receiving front-line cancer-directed therapy
- Child diagnosed with de novo cancer
- Child has established care at a study site and initiated cancer directed therapy in the prior 2-months
- Child planned to receive at least 4-months of cancer-directed therapy at study site from time of diagnosis per initial cancer treatment plan
- Child is <18 years at time of enrollment

... and 11 more (see full listing online)

Exclusion (11)

- Cohort 1: Poverty-exposed children with cancer receiving front-line cancer-directed therapy
- Planned transfer of child to a non-DFCI or non-Columbia facility for cancer-directed therapy
- Foreign national family receiving care as an Embassy-pay patient
- Child is enrolled on embedded correlative health equity aims of open or upcoming clinical drug trials which are powered on descriptive parent-reported poverty data (e.g. AALL1731, DFCI 25-001). Co-enrollment on a poverty intervention study would confound the specified endpoints of these open trial correlative studies
- Child or household member receiving SSI

... and 6 more (see full listing online)

Locations (4 total)

University of California San Francisco, San Francisco, California, United States

Boston Children's Hospital, Boston, Massachusetts, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

... and 1 more locations